Evidence for an imbalance between tau O-GlcNAcylation and phosphorylation in the hippocampus of a mouse model of Alzheimer's disease

Pharmacological Research

Volumn 105, Issue , 2016, Pages 186-197

  Gatta, Eleonora ^a,b,h   Lefebvre, Tony ^a   Gaetani, Silvana ^b   Dos Santos, Marc ^c   Marrocco, Jordan ^b,d,h   Mir, Anne Marie ^a   Cassano, Tommaso ^e   MacCari, Stefania ^a,b,h   Nicoletti, Ferdinando ^b,f   Mairesse, Jérôme ^g  

^a UNIV LILLE   (France)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c and Centre National de la Recherche Scientifique Unité Mixte de Recherche 8246   (France)

^d ROCKEFELLER UNIVERSITY   (United States)

^e UNIVERSITY OF FOGGIA   (Italy)

^f IRCCS NEUROMED   (Italy)

^g HÔPITAL ROBERT DEBRÉ   (France)

^h UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

Author keywords

3xTg AD mice; hippocampus; O GlcNAcylation; tau protein

Indexed keywords

GLUTAMINE FRUCTOSE 6 PHOSPHATE AMINOTRANSFERASE; HYDROLASE; O LINKED N ACETYLGLUCOSAMINE TRANSFERASE; O N ACETYLGLUCOSAMINE HYDROLASE; TAU PROTEIN; TRANSFERASE; UNCLASSIFIED DRUG; N ACETYLGLUCOSAMINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; FRONTAL CORTEX; HIPPOCAMPUS; MALE; MOUSE; MOUSE MODEL; NONHUMAN; O N ACETYLGLUCOSAMINE GLYCOSYLATION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; ACYLATION; ANIMAL; BRAIN; DISEASE MODEL; GLYCOSYLATION; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ACETYLGLUCOSAMINE; ACYLATION; ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; GLYCOSYLATION; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; TAU PROTEINS;

EID: 84958034402     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.01.006     Document Type: Article

References (56)

1. C.S. Arnold, G.V. Johnson, R.N. Cole, D.L. Dong, M. Lee, and G.W. Hart The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine J. Biol. Chem. 271 1996 28741 28744
2. D. Arsenault, C. Julien, C. Tremblay, and F. Calon DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice PLoS One 6 2011 10.1371/journal.pone.0017397 e17397
3. D. Baglietto-Vargas, M. Kitazawa, E.J. Le, T. Estrada-Hernandez, C.J. Rodriguez-Ortiz, R. Medeiros, K.N. Green, and F.M. LaFerla Endogenous murine tau promotes neurofibrillary tangles in 3xTg-AD mice without affecting cognition Neurobiol. Dis. 62 2014 407 -415 10.1016/j.nbd.2013.10.019
4. K. Baumann, E.M. Mandelkow, J. Biernat, H. Piwnica-Worms, and E. Mandelkow Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5 FEBS Lett. 336 1993 417 424
5. L.M. Billings, S. Oddo, K.N. Green, J.L. McGaugh, and F.M. LaFerla Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice Neuron 45 2005 675 688 10.1016/j.neuron.2005.01.040
6. P. Borghgraef, C. Menuet, C. Theunis, J.V. Louis, H. Devijver, H. Maurin, C. Smet-Nocca, G. Lippens, G. Hilaire, H. Gijsen, D. Moechars, and F. Van Leuven Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice PLoS One 8 2013 10.1371/journal.pone.0084442 e84442
7. A. Caccamo, S. Oddo, L.X. Tran, and F.M. LaFerla Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles Am. J. Pathol. 170 5 2007 1669 1675
8. J.C. Carroll, E.R. Rosario, L. Chang, F.Z. Stanczyk, S. Oddo, F.M. LaFerla, and C.J. Pike Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice J. Neurosci. 27 2007 13357 13365 10.1523/JNEUROSCI.2718-07.2007
9. L.K. Clinton, L.M. Billings, K.N. Green, A. Caccamo, J. Ngo, S. Oddo, J.L. McGaugh, and F.M. LaFerla Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice Neurobiol. Dis. 28 2007 76 -82 10.1016/j.nbd.2007.06.013
10. S. Cunnane, S. Nugent, M. Roy, A. Courchesne-Loyer, E. Croteau, S. Tremblay, A. Castellano, F. Pifferi, C. Bocti, N. Paquet, H. Begdouri, M. Bentourkia, E. Turcotte, M. Allard, P. Barberger-Gateau, T. Fulop, and S.I. Rapoport Brain fuel metabolism, aging, and Alzheimer's disease Nutrition 27 2011 3 20 10.1016/j.nut.2010.07.021
11. S.M. De la Monte, and M. Tong Brain metabolic dysfunction at the core of Alzheimer's disease Biochem. Pharmacol. 88 2014 548 559 10.1016/j.bcp.2013.12.012
12. N. Din, I. Ahmad, I. Ul Haq, S. Elahi, D.C. Hoessli, and A.R. Shakoori The function of GluR1 and GluR2 in cerebellar and hippocampal LTP and LTD is regulated by interplay of phosphorylation and O-GlcNAc modification J. Cell. Biochem. 109 2010 585 -597 10.1002/jcb.22436
13. F. Ding, J. Yao, J.R. Rettberg, S. Chen, and R.D. Brinton Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention PLoS One 8 2013 10.1371/journal.pone.0079977 e79977
14. M. Filali, R. Lalonde, P. Theriault, C. Julien, F. Calon, and E. Planel Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD) Behav. Brain Res. 234 2012 334 -342 10.1016/j.bbr.2012.07.004
15. S. Förster, A.S. Welleford, J.C. Triplett, R. Sultana, B. Schmitz, and D.A. Butterfield Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain Biochim. Biophys. Acta 1842 2014 1333 -1339 10.1016/j.bbadis.2014.05.014
16. L. Giménez-Llort, G. Blázquez, T. Cañete, B. Johansson, S. Oddo, A. Tobeña, F.M. LaFerla, and A. Fernández-Teruel Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid Neurosci. Biobehav. Rev. 31 2007 125 -147 10.1016/j.neubiorev.2006.07.007
17. M.L. Giuffrida, F. Caraci, P. De Bona, G. Pappalardo, F. Nicoletti, E. Rizzarelli, and A. Copani The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology Rev. Neurosci. 21 2010 83 93
18. D.L. Graham, A.J. Gray, J.A. Joyce, D. Yu, J. OMoore, G.A. Carlson, M.S. Shearman, T.L. Dellovade, and H. Hering Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy Neuropharmacology 79 2014 307 -313 10.1016/j.neuropharm.2013.11.025
19. L.S. Griffith, and B. Schmitz O-linked N-acetylglucosamine is upregulated in Alzheimer brains Biochem. Biophys. Res. Commun. 213 1995 424 -431 10.1006/bbrc.1995.2149
20. D.P. Hanger, K. Hughes, J.R. Woodgett, J.P. Brion, and B.H. Anderton Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase Neurosci. Lett. 147 1992 58 62
21. J.A. Hanover, M.W. Krause, and D.C. Love Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation Nat. Rev. Mol. Cell Biol. 13 2012 312 321 10.1038/nrm3334
22. G.W. Hart, C. Slawson, G. Ramirez-Correa, and O. Lagerlof Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease Annu. Rev. Biochem. 80 2011 825 858 10.1146/annurev-biochem-060608-102511
23. M.J. Kang, C. Kim, H. Jeong, B.-K. Cho, A.L. Ryou, D. Hwang, I. Mook-Jung, and E.C. Yi Synapsin-1 and tau reciprocal O-GlcNAcylation and phosphorylation sites in mouse brain synaptosomes Exp. Mol. Med. 45 2013 e29 10.1038/emm.2013.56
24. T. Lefebvre, S. Ferreira, L. Dupont-Wallois, T. Bussière, M.-J. Dupire, A. Delacourte, J.-C. Michalski, and M.-L. Caillet-Boudin Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins - a role in nuclear localization Biochim. Biophys. Acta 1619 2003 167 176
25. T. Lefebvre, C. Guinez, V. Dehennaut, O. Beseme-Dekeyser, W. Morelle, and J.-C. Michalski Does O-GlcNAc play a role in neurodegenerative diseases? Expert Rev. Proteomics 2 2005 265 275 10.1586/14789450.2.2.265
26. S. Lim, M.M. Haque, G. Nam, N. Ryoo, H. Rhim, and Y.K. Kim Monitoring of intracellular tau aggregation regulated by OGA/OGT inhibitors Int. J. Mol. Sci. 16 9 2015 20212 20224
27. F. Liu, T. Zaidi, K. Iqbal, I. Grundke-Iqbal, R.K. Merkle, and C.X. Gong Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease FEBS Lett. 512 2002 101 106
28. F. Liu, K. Iqbal, I. Grundke-Iqbal, G.W. Hart, and C.-X. Gong O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease Proc. Natl. Acad. Sci. U. S. A. 101 2004 10804 -10809 10.1073/pnas.0400348101
29. F. Liu, J. Shi, H. Tanimukai, J. Gu, J. Gu, I. Grundke-Iqbal, K. Iqbal, and C.-X. Gong Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease Brain 132 2009 1820 1832 10.1093/brain/awp099
30. Y. Liu, X. Li, Y. Yu, J. Shi, Z. Liang, X. Run, Y. Li, C.L. Dai, I. Grundke-Iqbal, K. Iqbal, F. Liu, and C.-X. Gong Developmental regulation of protein O-GlcNAcylation, O-GlcNAc transferase, and O-GlcNAcase in mammalian brain PLoS One 7 8 2012 e43724 10.1371/journal.pone.0043724
31. J. Jo, D.J. Whitcomb, K.M. Olsen, T.L. Kerrigan, S.C. Lo, G. Bru-Mercier, B. Dickinson, S. Scullion, M. Sheng, G. Collingridge, and K. Cho Aβ(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β Nat. Neurosci. 14 5 2011 545 -547 10.1038/nn.2785
32. M.A. Mastrangelo, and W.J. Bowers Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice BMC Neurosci. 9 2008 81 10.1186/1471-2202-9-81
33. S. Mondragón-Rodríguez, E. Trillaud-Doppia, A. Dudilot, C. Bourgeois, M. Lauzon, N. Leclerc, and J. Boehm Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation J. Biol. Chem. 287 38 2012 32040 32053 10.1074/jbc.M112.401240
34. R.L. Nelson, Z. Guo, V.M. Halagappa, M. Pearson, A.J. Gray, Y. Matsuoka, M. Brown, R.F. Clark, and M.P. Mattson Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice Exp. Neurol. 205 2007 166 176 10.1016/j.expneurol.2007.01.037
35. R.M. Nicholson, Y. Kusne, L.A. Nowak, F.M. LaFerla, E.M. Reiman, and J. Valla Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models Brain Res. 1347 2010 179 -185 10.1016/j.brainres.2010.05.084
36. S. Oddo, A. Caccamo, J.D. Shepherd, M.P. Murphy, T.E. Golde, R. Kayed, R. Metherate, M.P. Mattson, Y. Akbari, and F.M. LaFerla Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction Neuron 39 2003 409 421
37. S. Oddo, A. Caccamo, D. Cheng, B. Jouleh, R. Torp, and F.M. LaFerla Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice J. Neurochem. 102 4 2007 1053 -1063
38. R. Ossenkoppele, N. Tolboom, J.C. Foster-Dingley, S.F. Adriaanse, R. Boellaard, M. Yaqub, A.D. Windhorst, F. Barkhof, A.A. Lammertsma, P. Scheltens, W.M. van der Flier, and B.N.M. van Berckel Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET Eur. J. Nucl. Med. Mol. Imaging 39 2012 990 1000 10.1007/s00259-012-2102-3
39. A. Parachikova, V. Vasilevko, D.H. Cribbs, F.M. LaFerla, and K.N. Green Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation J. Alzheimers Dis. 21 2 2010 527 -542 10.3233/JAD-2010-100204
40. P. Regan, T. Piers, J.H. Yi, D.H. Kim, S. Huh, S.J. Park, J.H. Ryu, D.J. Whitcomb, and K. Cho Tau phosphorylation at serine 396 residue is required for hippocampal LTD J. Neurosci. 35 12 2015 4804 4812 10.1523/JNEUROSCI.2842-14.2015
41. E.M. Reiman, R.J. Caselli, L.S. Yun, K. Chen, D. Bandy, S. Minoshima, S.N. Thibodeau, and D. Osborne Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E N. Engl. J. Med. 334 1996 752 758 10.1056/NEJM199603213341202
42. A. Romano, L. Pace, B. Tempesta, A.M. Lavecchia, T. Macheda, G. Bedse, A. Petrella, C. Cifani, G. Serviddio, G. Vendemiale, S. Gaetani, and T. Cassano Depressive-like behavior is paired to monoaminergic alteration in a murine model of Alzheimer's disease Int. J. Neuropsychopharmacol. 18 2014 10.1093/ijnp/pyu020
43. D.J. Selkoe Alzheimer's disease: genes proteins, and therapy Physiol. Rev. 81 2001 741 766
44. O.A. Shipton, J.R. Leitz, J. Dworzak, C.E. Acton, E.M. Tunbridge, F. Denk, H.N. Dawson, M.P. Vitek, R. Wade-Martins, O. Paulsen, and M. Vargas-Caballero Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation J. Neurosci. 31 5 2011 1688 1692 10.1523/JNEUROSCI.2610-10.2011
45. Y. Skorobogatko, A. Landicho, R.J. Chalkley, A.V. Kossenkov, G. Gallo, and K. Vosseller O-linked β-N-acetylglucosamine (O-GlcNAc) site thr-87 regulates synapsin I localization to synapses and size of the reserve pool of synaptic vesicles J. Biol. Chem. 289 2014 3602 -3612 10.1074/jbc.M113.512814
46. G.W. Small, J.C. Mazziotta, M.T. Collins, L.R. Baxter, M.E. Phelps, M.A. Mandelkern, A. Kaplan, A. La Rue, C.F. Adamson, and L. Chang Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease JAMA 273 1995 942 947
47. E. Steen, B.M. Terry, E.J. Rivera, J.L. Cannon, T.R. Neely, R. Tavares, X.J. Xu, J.R. Wands, and S.M. de la Monte Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J. Alzheimers Dis. 7 2005 63 80
48. M. Takahashi, Y. Tsujioka, T. Yamada, Y. Tsuboi, H. Okada, T. Yamamoto, and Z. Liposits Glycosylation of microtubule-associated protein tau in Alzheimer's disease brain Acta Neuropathol. 97 1999 635 641
49. M.K. Tallent, N. Varghis, Y. Skorobogatko, L. Hernandez-Cuebas, K. Whelan, D.J. Vocadlo, and K. Vosseller In vivo modulation of O-GlcNAc levels regulates hippocampal synaptic plasticity through interplay with phosphorylation J. Biol. Chem. 284 2009 174 181 10.1074/jbc.M807431200
50. E.W. Taylor, K. Wang, A.R. Nelson, T.M. Bredemann, K.B. Fraser, S.M. Clinton, R. Puckett, R.B. Marchase, J.C. Chatham, and L.L. McMahon O-GlcNAcylation of AMPA receptor GluA2 is associated with a novel form of long-term depression at hippocampal synapses J. Neurosci. 34 2014 10 21 10.1523/JNEUROSCI.4761-12.2014
51. J.Z. Wang, I. Grundke-Iqbal, and K. Iqbal Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease Nat. Med. 2 1996 871 -875
52. S.J. Webster, A.D. Bachstetter, P.T. Nelson, F.A. Schmitt, and L.J. Van Eldik Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models Front. Genet. 5 88 2014 10.3389/fgene.2014.00088
53. S.A. Yuzwa, X. Shan, M.S. Macauley, T. Clark, Y. Skorobogatko, K. Vosseller, and D.J. Vocadlo Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation Nat. Chem. Biol. 8 2012 393 -399 10.1038/nchembio.797
54. S.A. Yuzwa, A.H. Cheung, M. Okon, L.P. McIntosh, and D.J. Vocadlo O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers J. Mol. Biol. 426 2014 1736 1752 10.1016/j.jmb.2014.01.004
55. S.A. Yuzwa, X. Shan, B.A. Jones, G. Zhao, M.L. Woodward, X. Li, Y. Zhu, E.J. McEachern, M.A. Silverman, N.V. Watson, C.-X. Gong, and D.J. Vocadlo Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice Mol. Neurodegener. 9 2014 42 10.1186/1750-1326-9-42
56. S.A. Yuzwa, X. Shan, B.A. Jones, G. Zhao, M.L. Woodward, X. Li, Y. Zhu, E.J. McEachern, M.A. Silverman, N.V. Watson, C.-X. Gong, and D.J. Vocadlo Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice Mol. Neurodegener. 9 2014 42 10.1186/1750-1326-9-42